Pain Control and Side Effects in Cesarean Section Anesthesia: Comparison of Intrathecal Morphine and Fentanyl

NCT ID: NCT07144410

Last Updated: 2025-08-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 180 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-08-01
• Study Completion Date: 2025-10-31

Brief Summary

Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. However, its postoperative analgesic duration is limited, but in contrast, morphine, a hydrophilic opioid, provides prolonged postoperative pain control but has a slower onset and a higher incidence of adverse effects, notably nausea and vomiting. This prospective, randomized, double-blind, parallel study enrolled 180 parturients scheduled for elective cesarean section, all receiving spinal anesthesia with hyperbaric bupivacaine (7.5-10 mg, adjusted to height) plus either intrathecal fentanyl 25 µg (F group) or intrathecal morphine 100 µg and fentanyl 25µg (M+F group). Primary outcomes include intraoperative and postoperative pain scores, systemic opioid consumption, and patient satisfaction, while secondary outcomes assess the incidence of opioid-related side effects.

Detailed Description

Eligible patients will be allocated in a 1:1 ratio into one of two groups:

Group F (Fentanyl): Hyperbaric bupivacaine 0.5% combined with fentanyl 25 µg. Group M+F (Morphine + Fentanyl): Hyperbaric bupivacaine 0.5% combined with morphine 100 µg and fentanyl 25 µg.

The dose of hyperbaric bupivacaine (7.5-11 mg) will be determined according to patient height. Randomization will be performed using the envelope technique. Two anesthetists will participate in each case: The first anesthetist will perform the spinal anesthesia and will remain blinded to the drug solution. The second anesthetist will open the allocation envelope, prepare the assigned intrathecal solution, and provide it to the first anesthetist. All drugs will be sourced from the same manufacturer to ensure uniformity.

During the pre-anesthetic visit, all patients will receive detailed information regarding the aims of the study, the planned anesthetic technique, the postoperative analgesia regimen, and the use of the Numeric Pain Rating Scale (NPS). Demographic and clinical data will be collected, including height, term weight, age, smoking status, obstetric history (gesta/para), presence of preoperative contractions, full medical history, current medications, and any allergies.

An 18G intravenous cannula will be inserted, and 500 mL of Ringer lactate will be infused prior to anesthesia. All participants will fast preoperatively and will receive pantoprazole 40 mg and metoclopramide 10 mg as premedication.

Spinal anesthesia will be performed under aseptic conditions with the patient in the sitting position at the L3-L4 interspace using a 27G Whitacre needle via a midline approach. Local infiltration with 2 mL of 1% lidocaine will precede dural puncture. The anesthetic mixture will be injected manually at a rate of 1 mL per 15 seconds with a barbotage technique.

Following injection, patients will be placed in the supine position with left uterine displacement using a roll wedge under the right hip. Warmed Ringer lactate will be administered at a rate of 10-20 mL/kg/h throughout the perioperative period. All patients will wear anti-embolic stockings on the lower limbs.

Surgery will begin once sensory block (assessed by the cold test) reaches the T4 dermatome. Non-invasive blood pressure (BP) will be measured every minute until delivery and every 3-5 minutes thereafter; heart rate (HR) and oxygen saturation (SpO₂) will be continuously monitored. A systolic BP decrease below baseline will be treated with intravenous ephedrine 5-15 mg, repeated every minute as required until BP is restored. Oxytocin 5 IU will be administered intravenously at delivery, followed by additional doses if clinically indicated. Granisetron 1 mg IV and dexamethasone 4 mg IV will be administered at the start of surgery; granisetron 1 mg will be repeated 12 hours later. Additional antiemetics will be given as required.

Postoperative analgesia will be obtained by 1 g of Paracetamol every 6 hours and Ibuprofen 400 mg every 8 hours, administered either intravenously or orally. As a reserve pain control for high intesity pain Tramadol 50-100 mg IV will be given every 6 hours as required, with a maximum daily dose of 400 mg.

Data will be recorded for the following parameters:Demographic variables as age, weight, height, smoking status, obstetric history, preoperative contractions. Time from anesthesia induction to surgical incision, time to achieve sensory block.

Pain scores will be assessed at surgical incision, at the end of surgery, and postoperatively at 4, 6, 12, 24, 48, and 72 hours, both at rest and during mobilization. Side effects such as the incidence and severity of pruritus (graded), nausea, vomiting, oversedation, dizziness, and respiratory depression. Maximum motor block using the 4-point Bromage scale, time to complete motor recovery, and sensory block level determined by the cold test.

Pain intensity will be evaluated using the Numeric Pain Rating Scale (0 = no pain; 10 = worst pain imaginable) at all scheduled postoperative time points. But for a more comprehensively comparison of the post-operative pain in the study groups, two additional assessment metrics will be employed:

1. time-weighted sum pain intensity differences over 72 hours

2. sum pain intensity differences area over 72 hours Descriptive statistics will include the observed frequency counts (percentage) for categorical variables; and mean ± standard deviation for numerical variables, irrespective of their distribution. Normality will be tested with the Kolmogorov-Smirnov test. For comparing means in normally distributed values, the t-test for independent samples will be applied, with Levene's test for equality of variances. For comparing distribution of non-normally distributed numerical values, the non-parametric Mann-Whitney U statistical tests will be applied and median (Inter-Quartile Range) with Tukey's hinges will be additionally provided as a descriptive statistic.

The Chi-square statistical test (either asymptotic, Fisher's exact test, or Monte-Carlo simulation with 10,000 samples) will be applied to check the statistical significance of the association between the categorical variables. The odds ratio (OR) values will be calculated for the symptoms associated with the two anesthetics, such as nausea and dizziness.

The statistical analysis will be conducted at a 95% level of confidence and a 5% level of statistical significance. All reported probability values will be two-tailed.

Statistical analysis will be performed with the statistical software IBM SPSS v. 20 and open source R v.4.0.5 packages.The study will be conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of Pelican Hospital from Oradea (no.1689/25.08.2025).

Conditions

Anaesthesia, Spinal

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Fentanyl, Morphine and Bupivacaine

Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl, Morphine and Bupivacaine

fentanyl + morphine

Intervention Type: DRUG

The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.

Fentanyl and Bupivacaine

Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl and Bupivacaine

fentanyl

Intervention Type: DRUG

The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.

Interventions

fentanyl + morphine

The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.

Intervention Type: DRUG

fentanyl

The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.

Intervention Type: DRUG

Other Intervention Names

plus bupivacaine; plus bupivacaine

Eligibility Criteria

Inclusion Criteria

• American Society of Anesthesiologists (ASA) physical status class I-II.
• Absence of significant past medical conditions.
• No documented hypersensitivity to any study drug.
• No history of chronic pain syndromes or regular analgesic consumption.
• No anxiety or depressive disorders diagnosis.
• Body weight ≥ 50 kg.
• Scheduled for elective cesarean delivery.
• Single fetus.

Exclusion Criteria

• Patient refusal.
• Contraindication of spinal anaesthesia.
• Conversion from a natural delivery with or without an epidural anaesthesia started.
• History of substance abuse or drug dependence.
• Presence of acute or chronic fetal distress.
• Preeclampsia.
• Allergic reaction occurring after enrollment.
• Refusal to receive protocol-specified analgesics or medications.
• Requirement for surgical re-intervention within 72 hours postoperatively.
• Previous administration of opioids or other central nervous system depressants prior to intervention.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Oradea Pelican Clinic Hospital

UNKNOWN

Sponsor Role: collaborator

University of Oradea

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aurel Mohan, MD, PhD

Role: STUDY_CHAIR

Head of Surgery Department of Medicine and Pharmacy Faculty of Oradea

Locations

University of Oradea, Pelican Clinic Hospital

Oradea, Bihor County, Romania

Countries

Romania

Other Identifiers

08FvM_Medical Study

Identifier Type: -

Identifier Source: org_study_id